The 3 Supplements With Genuine Clinical Evidence — and 5 You Should Stop Buying
The longevity supplement market is worth billions and full of beautiful nonsense — here's how to tell the difference.
The supplement aisle has a confidence problem. Not the kind where it’s too shy, but the opposite: every bottle promises to reverse aging, ignite your mitochondria, and add a decade to your healthspan. Most of these promises are built on mouse studies, wishful thinking, and the breathless enthusiasm of people trying to sell you something. The longevity supplement industry pulled in billions of dollars last year on the strength of science that, in many cases, hasn’t yet survived contact with actual human bodies in controlled trials.
I want to be fair here. The field is moving fast. Some compounds that looked unpromising in 2020 now have decent human data. And some supplements that longevity influencers have been pushing for years have quietly failed to replicate in rigorous trials. So let’s do this properly: here are the three supplements with the strongest clinical evidence in humans right now, and five you’re probably spending money on that the science doesn’t yet justify. 🔬
The 3 that actually have the evidence
Omega-3 fatty acids: still the most defensible bet
Omega-3s — specifically EPA and DHA, the long-chain fatty acids found in fatty fish and fish oil — have the broadest and deepest evidence base of any longevity supplement. Not because of any single dramatic trial, but because the supporting literature is enormous and remarkably consistent across different populations, study designs, and outcomes.
The most recent and compelling human data comes from two large trials:
The DO-HEALTH trial (777 older adults, randomized, double-blind) found that 1 gram per day of omega-3 supplementation slowed biological aging markers on multiple epigenetic clocks by 2.9 to 3.8 months over three years. Effects were additive when combined with vitamin D and exercise.
A UK Biobank analysis of more than 117,000 participants, published in 2024, found that higher plasma DHA levels were linked to significantly lower risk of death from cardiovascular disease, cancer, and all causes combined — extending omega-3 associations well beyond heart health alone.
A 2025 analysis described the effect as equivalent to a small but measurable reduction in biological age. Let me be honest about what “2.9 to 3.8 months” on an epigenetic clock actually means — it’s modest. It doesn’t prove you’ll live longer. But the cardiovascular and anti-inflammatory evidence is decades deep, the safety profile is excellent, and the effect on epigenetic clocks points in the right direction at a biologically plausible dose. 💊
The dose that matters in the human trials is roughly 1 gram per day of combined EPA+DHA — not total fish oil, but the active components specifically. Many cheap fish oil capsules are poorly concentrated. Check the label for actual EPA/DHA content, not just “fish oil 1000mg” which could mean anything.
Are you eating fatty fish — salmon, sardines, mackerel — at least twice a week? If yes, you may not need to supplement. If no, this is probably the first supplement worth considering.
Creatine monohydrate: the boring one that quietly works
Creatine monohydrate is not glamorous. It doesn’t come in a black bottle with a skull on it, and nobody at a longevity conference will try to sell you on its revolutionary molecular mechanisms. It’s been around for decades, it’s extensively studied, it’s cheap, and it works. 💪
For aging specifically, the human evidence is building in three directions:
Muscle and bone: A 2025 review in Frontiers in Physiology confirmed that creatine supplementation combined with resistance training significantly improves muscle strength, lean body mass, and functional capacity in older adults. This matters enormously because muscle loss — sarcopenia — is one of the strongest predictors of frailty, falls, and early death.
Cognitive function: A 2025 systematic review in Nutrition Reviews covering multiple databases found that creatine is associated with benefits for cognition in generally healthy older adults, particularly for memory, processing speed, and executive function. The review noted that effects are strongest in individuals with lower baseline creatine levels — which includes vegetarians and older adults, whose dietary creatine intake is often low.
Energy metabolism: Creatine replenishes phosphocreatine in cells, supporting the ATP system that powers short, intense muscular effort. But it also supports mitochondrial stability and antioxidant defenses, according to a 2026 review from Henan Polytechnic University — mechanisms that overlap with broader aging biology.
The caveats are mild: creatine can cause water retention in muscle tissue (not the bad kind — it’s inside the cells), and it should be avoided by people with kidney disease. For everyone else, 3 to 5 grams per day of plain creatine monohydrate — not “advanced matrix” or “buffered” formulations, which cost more and perform no better — is one of the best cost-to-benefit ratios in the entire supplement space. 🧬
Think of creatine as the supplement that does three things health-conscious people over 40 actually need: maintains muscle, supports the brain, and costs about 50 cents a day.
Vitamin D3: not magic, but probably non-negotiable
Vitamin D3 sits in an interesting position. The mortality data from randomized trials is mixed — some large meta-analyses find modest all-cause mortality reductions, others don’t. But two specific findings from the last two years have strengthened the case for D3 in longevity contexts considerably. ⚡
First, the VITAL trial — a large, randomized, placebo-controlled study — published data in 2025 in The American Journal of Clinical Nutrition showing that 2,000 IU per day of vitamin D3 was associated with significantly less telomere shortening over four years. The estimated effect was equivalent to about three years of reduced biological aging. Telomere preservation isn’t a perfect proxy for longevity, but telomere shortening is a recognized hallmark of cellular aging, and a four-year randomized trial showing meaningful preservation is not trivial.
Second, the Intermountain Health TARGET-D trial, presented at the American Heart Association Scientific Sessions in late 2025, found that targeted vitamin D3 treatment in patients who had recently had a heart attack dramatically reduced the risk of a second cardiac event. That’s a specific clinical population, but it illustrates how real the cardiovascular effects can be.
Here’s the practical reality that makes D3 nearly universal:
Most adults in northern latitudes are deficient or insufficient, particularly in winter
Deficiency is linked to worse outcomes across cardiovascular, immune, metabolic, and cognitive domains
The cost is trivial and the risk of harm at standard doses (1,000 to 2,000 IU per day) is very low
The DO-HEALTH trial found D3 and omega-3 together had additive effects on epigenetic aging markers
Get your 25-hydroxy vitamin D blood level tested. If you’re below 30 ng/mL, this isn’t optional — it’s a basic correction. If you’re above 50, supplementing aggressively likely adds nothing and high doses above 4,000 IU daily carry genuine risk of hypercalcemia. The goal is sufficiency, not flooding the system. 💡
The 5 you should probably stop buying
Resveratrol: a great mouse story with a disappointing human sequel
Resveratrol became famous after research showed it could extend lifespan in yeast, worms, and some vertebrate models by activating a family of proteins called sirtuins, which mimic the effects of calorie restriction. David Sinclair at Harvard built part of his public profile around it. GlaxoSmithKline bought a resveratrol biotech company for $720 million.
Then the human trials happened.
A comprehensive 2024 systematic review published in the International Journal of Molecular Sciences examined every clinical trial conducted with purified resveratrol across multiple conditions. The conclusion: there is currently no conclusive clinical evidence to advocate resveratrol’s recommendation in any healthcare setting. Bioavailability is the central problem — most orally ingested resveratrol is metabolized so rapidly in the gut and liver that meaningful concentrations never reach target tissues. The gut microbiome converts it into metabolites with highly variable activity depending on the individual.
At a January 2025 longevity roundtable published by Peter Attia, biogerontologist Matt Kaeberlein was blunt: “You never see people studying resveratrol in the aging field anymore. I think if you went to a conference and asked scientists, what do you think about resveratrol? You’d get the same answer.” GlaxoSmithKline quietly shut the resveratrol operation down years ago after the results didn’t materialize. 🚫
The mouse lifespan studies failed to replicate. The NIH’s Interventions Testing Program — the gold standard for longevity compound testing across multiple independent labs — did not find lifespan extension. This doesn’t mean resveratrol is useless for everything, but the case for buying it as a longevity supplement is much weaker than the marketing suggests.
Collagen peptides: probably just expensive protein
The collagen supplement market is enormous, and the pitch is intuitive: your body makes less collagen as you age, so swallow some collagen and... replenish it? Unfortunately, digestion doesn’t work that way. Your gut breaks down collagen into amino acids, which your body then uses however it sees fit — not preferentially for skin or joints. 🙅
A 2025 meta-analysis published in The American Journal of Medicine, covering 23 randomized controlled trials and 1,474 participants, found something damning: when studies funded by pharmaceutical companies were stripped out of the analysis, collagen supplements showed no statistically significant effect on skin hydration, elasticity, or wrinkles. The significant results in the pooled analysis came almost entirely from industry-sponsored trials. High-quality, independently funded studies consistently found no effect.
The collagen industry pushed back hard, arguing the methodology was flawed and pointing to individual well-designed trials that showed benefits. This is a live scientific dispute, and I won’t pretend there’s total consensus. But the pattern — effects in industry-funded studies, no effects in independent ones — is exactly the kind of signal that should make you pause before buying.
If you want the amino acids in collagen (mostly glycine and proline), a regular protein supplement — or simply eating enough protein — is cheaper and has a cleaner evidence record.
NMN and NR: fascinating, but years ahead of the human evidence
NMN (nicotinamide mononucleotide) and NR (nicotinamide riboside) are precursors to NAD+, the coenzyme that powers DNA repair, mitochondrial function, and cellular energy production. NAD+ levels decline with age. The logic for supplementing is therefore elegant, and the animal data is genuinely interesting. 🧬
The problem is the human data hasn’t caught up.
NPR’s coverage in May 2026 of the NAD+ supplement space quoted Dr. Samuel Klein, a researcher from Washington University School of Medicine: “The data in humans are pretty iffy right now that it actually has significant benefits.” Small trials have shown that NMN and NR do raise blood NAD+ levels in humans — that part works. But raising a biomarker and generating a meaningful health outcome are different things. Human trials have returned mixed results on metabolic health, and the trials that showed benefits (improved insulin sensitivity, walking speed, sleep quality) were small, short, and often in specific populations.
As of mid-2026, there is no large, long-term randomized controlled trial showing that NMN or NR supplementation meaningfully improves health outcomes in generally healthy adults. The preclinical science is exciting. The investment in research is serious. But at $60 to $150 per month, you’re currently paying to be an early adopter of a hypothesis, not a proven therapy. If you’re curious and can afford it, this may not be irrational — but go in clear-eyed about what the evidence does and doesn’t show.
The LongevityHub article on 6 supplements with actual evidence for slowing aging covers the NAD+ precursor debate in more depth if you want to dig into the nuance.
Turmeric/curcumin supplements: the bioavailability problem is real
Raw curcumin — the active compound in turmeric — is genuinely interesting in the lab. It has antioxidant and anti-inflammatory activity, it modulates pathways like AMPK and SIRT1, and the in vitro and animal data suggests it could be useful for aging biology. The issue is that curcumin is poorly absorbed by the human body. Standard curcumin supplements pass through your gut mostly intact. 🌿
A 2025 review in Frontiers in Pharmacology, synthesizing 25 meta-analyses of curcumin clinical trials, rated most of those meta-analyses as very low quality or low quality. Doses ranged from 50 mg to 6,000 mg across trials. Study durations varied wildly. The American Council on Science and Health summarized the situation in May 2026: “clinical benefits appear modest, inconsistent, and often supported by studies with important methodological limitations, while higher-bioavailability formulations have been linked to rare but serious adverse effects.”
The “enhanced bioavailability” versions — combined with black pepper extract (piperine), or in lipid formulations — do absorb better, but some of these formulations have their own safety questions. And “absorbs better” still doesn’t mean “produces robust clinical outcomes in humans.”
Eating turmeric as a spice in food is probably fine and possibly mildly beneficial. Spending $40 a month on a curcumin supplement without a specific clinical reason is harder to justify with current evidence.
Collagen-based “beauty supplements” and most antioxidant megadoses
This category is worth a brief mention because it captures a class of products — antioxidant megadoses like high-dose vitamin C, vitamin E, beta-carotene, and various proprietary blends — that genuinely failed in rigorous human trials and, in some cases, caused harm. 💊
The CARET trial found that high-dose beta-carotene supplementation increased lung cancer risk in smokers. The HOPE trial found that high-dose vitamin E had no benefit and may have increased heart failure risk. High-dose antioxidant supplements have, in multiple large trials, been neutral to harmful compared to placebo. The logic sounds good — oxidative stress accelerates aging, so take antioxidants — but the body’s antioxidant systems are tightly regulated, and flooding them with exogenous antioxidants appears to disrupt that regulation rather than help it.
This doesn’t apply to correcting genuine deficiencies, or to moderate food-derived antioxidant intake. It applies specifically to the high-dose supplement products marketed as anti-aging solutions based on the antioxidant hypothesis. That hypothesis, in isolation, has not held up.
How to think about the rest
The supplement market doesn’t map neatly onto this article. There are compounds in genuinely promising middle territory — magnesium (probably useful for most people, particularly for sleep and metabolic health), vitamin K2 (sensible alongside D3), spermidine (interesting early human data, worth watching) — that didn’t make either list because the evidence is real but limited.
The principle that separates the three from the five is simple: do we have replicated, independently funded, randomized controlled trials in humans showing a clinically meaningful outcome? For omega-3s, creatine, and vitamin D3 at appropriate doses, the answer is yes, or at minimum “convincingly trending yes.” For the five in the second list, the answer is currently no — fascinating biology, inadequate human proof. The LongevityHub breakdown of what longevity scientists actually take themselves shows a similar pattern — the researchers closest to the evidence tend to start with the unglamorous basics rather than the headline-grabbing molecules.
The supplement companies have strong financial incentives to generate the kind of small, short, industry-funded studies that produce positive results. Independent replication is harder to fund and less commercially interesting. Your job as a consumer is to weight the evidence accordingly — not to dismiss all supplements, but to ask “who funded this, how large was it, and did it replicate?”
One last thing worth sitting with: the supplements with the worst evidence-to-marketing ratio tend to cost the most. Creatine monohydrate — the one with the deepest evidence base — is roughly 50 cents a day. Proprietary NMN blends are $100 a month and up. That ratio probably tells you something.
Which of these supplements are already in your cabinet — and does knowing the evidence base change anything about your plans?